epsteinbarr
viru
ebv
almost
ubiquit
human
gamma
herp
viru
infect
rest
human
blymphocyt
includ
bcll
cell
high
efficaci
ebv
bcell
tropism
mainli
due
viral
envelop
glycoprotein
interact
cellular
complement
receptor
b
cell
ebv
seroposit
individu
mainli
elicit
tcell
respons
exosom
endosomederiv
membran
vesicl
releas
cell
divers
origin
includ
dendrit
cell
cancer
cell
ebvinfect
b
cell
exosom
bud
endosom
membran
accumul
multivesicular
bodi
eventu
fuse
cellular
membran
releas
contain
vesicl
exosom
rich
lipid
membran
protein
like
mhc
molecul
tnfr
tetraspanin
specif
composit
depend
cell
origin
exosom
either
fuse
recipi
cell
membran
engulf
phagocyt
cell
way
exosom
protein
degrad
load
onto
mhc
class
ii
molecul
obvious
exosom
deliv
protein
cargo
immunogen
manner
effici
reactiv
specif
cell
clone
henc
exosom
induc
strong
epitopespecif
immun
respons
use
altern
transfer
strategi
use
gene
vector
promis
vaccin
chronic
lymphocyt
leukemia
bcell
origin
bcll
common
adult
leukemia
western
hemispher
bcll
consid
prototyp
diseas
undergo
immun
evas
malign
cell
lack
import
accessori
costimulatori
molecul
thu
despit
express
high
level
surfac
mhc
class
ii
molecul
presum
present
tumorassoci
antigen
epitop
leukem
cell
tend
induc
tumorspecif
tcell
anergi
typic
activ
cell
patient
show
significantli
reduc
express
ligand
complet
consequ
cell
bcll
patient
activ
cell
receptor
interact
howev
essenti
signal
subsequ
induct
immun
accessori
molecul
like
increas
antigenpres
capac
normal
bcll
cell
hand
ebvspecif
cellular
immun
rel
intact
patient
overcom
dysfunct
potenti
tumorreact
cell
patient
bcll
sever
approach
develop
reli
stimul
bcll
cell
pathway
includ
ectop
express
leukem
cell
aim
selfstimul
cell
summari
immunotherapi
bcll
promis
potenti
candid
molecul
improv
patient
immun
statu
eventu
clinic
outcom
robust
cellular
immun
bcll
patient
ebv
therefor
prompt
us
investig
potenti
tailor
exosom
redirect
immun
malign
b
cell
present
novel
approach
target
transfer
function
cellular
protein
b
cell
via
tailor
exosom
approach
dual
function
confer
bcell
tropism
exosom
specif
cotransf
protein
interest
ii
viral
neoantigen
cell
effici
reactiv
cell
proof
concept
show
tailor
exosom
cotransf
function
immun
accessori
molecul
bcll
cell
subsequ
stimul
express
surfac
molecul
like
stimul
autolog
tumor
ebvspecif
cell
ebv
profound
bcell
tropism
mainli
convey
major
ebv
glycoprotein
viral
envelop
ligand
cellular
b
cell
knew
previou
work
exosom
transport
ectop
express
protein
green
fluoresc
protein
gfp
presum
present
cargo
exosom
lumen
addit
sever
group
provid
evid
surfac
protein
incorpor
exosom
membran
therefor
ask
whether
could
also
becom
integr
part
exosom
confer
bcell
tropism
vesicl
answer
question
cotransfect
cell
express
plasmid
encod
gene
gfp
three
day
later
isol
vesicl
supernat
transfect
cell
describ
materi
method
analyz
immunoblot
presenc
exosom
marker
detect
vesicl
float
densiti
gradient
correspond
densiti
sucros
gradient
thu
densiti
describ
exosom
gradient
also
reveal
cosediment
exosom
marker
indic
natur
vesicl
exosom
figur
flow
cytometri
exosom
coupl
latex
bead
reveal
presum
locat
within
exosom
membran
could
target
specif
antibodi
figur
demonstr
confer
bcell
tropism
also
exosom
incub
exosom
pbmc
healthi
donor
one
day
quantifi
exosom
bind
measur
gfp
fluoresc
flow
cytometri
assay
reveal
exosom
ebvlik
tropism
bound
b
cell
cell
figur
phagocyt
cell
engulf
exosom
process
protein
lysosom
present
epitop
associ
mhc
class
ii
molecul
cell
util
potenti
exosom
specif
transfer
exogen
protein
b
cell
turn
may
activ
specif
cell
gener
exosom
carri
major
tegument
protein
ebv
either
alon
togeth
incub
purifi
b
cell
exosom
overnight
use
pbmc
stimul
autolog
tcell
clone
shown
figur
b
cell
incub
exosom
activ
tcell
clone
concentrationdepend
manner
wherea
b
cell
incub
exosom
activ
tcell
clone
result
demonstr
potenti
exosom
transfer
immunogen
foreign
protein
b
cell
activ
specif
lymphocyt
next
seri
experi
want
elucid
whether
exosom
cotransf
function
membran
protein
b
cell
model
system
also
potenti
practic
applic
chose
bcll
cell
express
becom
immunogen
upon
ectop
express
malign
cell
therefor
transfect
cell
express
plasmid
isol
exosom
describ
immunoblot
antibodi
demonstr
presenc
exosom
prepar
gradient
reveal
cosediment
figur
indic
presenc
protein
exosom
figur
addit
flow
cytometri
reveal
exosom
specif
bound
b
cell
bcll
patient
figur
answer
question
whether
exosom
function
cell
transfect
express
plasmid
either
alon
combin
express
plasmid
transfer
exosom
bcll
cell
measur
antibodi
flow
cytometri
shown
figur
exosom
carri
protein
effici
convey
surfac
express
bcll
cell
exosom
transfer
ineffici
bcll
cell
probabl
due
weak
interact
receptor
cell
surfac
order
investig
immun
accessori
function
load
bcll
cell
hla
ii
donor
either
exosom
exosom
cell
transfect
express
plasmid
exo
transfect
express
plasmid
exo
one
day
later
ad
cell
measur
activ
elisa
assay
demonstr
relev
tcell
recognit
bcll
cell
load
exosom
significantli
better
stimul
bcll
cell
load
exosom
figur
induct
accessori
molecul
costimulatori
molecul
death
receptor
bcll
cell
upon
incub
exosom
figur
exosom
cell
provid
explan
improv
recognit
lymphocyt
knew
previou
experi
pbmc
healthi
donor
incub
exosom
effici
restimul
autolog
tcell
clone
data
shown
experi
implic
equal
transfer
bcll
cell
exosom
act
neoantigen
bcll
cell
normal
infect
ebv
interest
aspect
bcll
patient
usual
maintain
robust
easili
recruit
cmv
ebvspecif
tcell
respons
although
cell
gener
function
impair
instanc
bcll
cell
infect
ebv
load
cmvpeptid
effici
kill
autolog
lymphocyt
bcll
patient
thu
aim
investig
whether
serv
viral
neoantigen
exosometr
leukem
cell
whether
cell
becom
target
autolog
lymphocyt
stimul
pbmc
bcll
patient
three
time
exosom
describ
elucid
specif
cytolyt
potenti
activ
cell
end
incub
autolog
pbmc
hour
either
exosom
exosom
unmodifi
exosom
left
untreat
next
day
cell
label
calcein
use
target
autolog
effector
cell
shown
figur
cell
gener
stimul
exosom
effici
kill
autolog
pbmc
activ
exosom
quantifi
releas
calcein
interest
observ
notabl
activ
cell
protein
pbmc
incub
exosom
nontransfect
cell
lyse
almost
extent
nonactiv
autolog
pbmc
experi
also
demonstr
pbmc
load
exosom
constantli
better
lyse
pbmc
load
exosom
prompt
us
investig
whether
cell
specif
account
improv
lysi
therefor
test
cytolyt
activ
cell
ebvinfect
lymphoblastoid
cell
lcl
known
target
cell
ebvneg
b
blast
match
healthi
donor
found
cell
effici
lyse
allogen
lcl
wherea
complet
ignor
ebvfre
b
blast
indic
presenc
ebvspecif
cell
effector
popul
figur
data
corrobor
stimul
pbmc
carri
exosom
effici
method
activ
bcll
cell
reactiv
expans
cll
ebvspecif
lymphocyt
bcll
patient
demonstr
bcll
cell
activ
exosom
achiev
activ
phenotyp
next
want
assess
whether
bcll
cell
becam
immunogen
autolog
ebv
cllspecif
cell
given
expect
low
number
cell
peripher
blood
stimul
pbmc
patient
bcll
three
time
within
day
lethal
irradi
autolog
pbmc
incub
differ
exosom
describ
one
typic
experi
shown
figur
first
stimul
day
pbmc
patient
consist
mainli
malign
b
cell
cell
third
round
stimul
cultur
incub
exosom
almost
exclus
contain
tcell
figur
total
stimul
exosom
yield
approxim
vital
cell
day
mean
cell
count
increas
respect
figur
total
cell
number
slightli
decreas
figur
contrast
viabl
cell
detect
cultur
treat
exosom
deriv
nontransfect
cell
left
untreat
thu
stimul
cell
bcll
cell
load
exosom
pow
rful
option
select
expand
specif
cell
bcll
patient
vitro
next
want
elucid
specif
cytolyt
activ
cell
detail
mention
restimul
cell
form
bcll
patient
effici
lyse
autolog
pbmc
activ
exosom
exosom
contain
therefor
cell
must
recogn
cellular
antigen
test
whether
cell
specif
bcllassoci
antigen
reactiv
incub
irradi
ebvneg
bblast
donor
neg
control
bblast
load
restrict
peptid
deriv
bcllassoci
antigen
name
mdm
shown
figur
peptideload
bblast
effici
lyse
cell
stimul
exosom
wherea
b
blast
load
peptid
complet
ignor
lysi
target
cell
effici
reduc
upon
addit
mhc
class
ispecif
antibodi
demonstr
antigen
specif
effector
cell
known
promis
candid
molecul
immunotherapi
bcll
increas
immunogen
tumor
cell
line
ectop
express
bcll
cell
shown
induc
express
import
costimulatori
adhes
molecul
leukem
cell
turn
effici
stimul
autolog
cell
principl
viral
gene
transfer
bcll
cell
suitabl
approach
induc
immunolog
reaction
vitro
vivo
low
transduct
effici
result
high
dose
viral
vector
may
induc
sever
side
effect
also
remain
major
concern
clinic
use
viral
vector
exosom
cellular
microvesicl
alreadi
demonstr
potenti
induc
specif
immun
respons
major
perman
cell
line
spontan
releas
exosom
supernat
easili
purifi
concentr
transfect
cell
express
plasmid
code
result
secret
modifi
exosom
carri
protein
upon
interact
target
b
cell
undetermin
fraction
exosom
presum
engulf
degrad
lysosom
way
peptid
exosom
protein
present
associ
mhc
class
ii
molecul
exosom
taken
target
cell
probabl
engag
proteinprotein
contact
cellular
surfac
molecul
lead
receptor
activ
signal
molecul
surfac
exosom
probabl
target
vesicl
exclus
human
b
cell
express
relev
amount
receptor
molecul
exosom
cotransf
thought
lead
effici
ligandreceptor
engag
bcell
surfac
activ
intrins
signal
cascad
treatment
bcll
cell
exosom
transfer
function
protein
caus
leukemia
cell
becom
effici
apc
activ
receptor
lead
induct
immun
accessori
molecul
make
leukem
cell
potent
stimul
autolog
lymphocyt
sinc
almost
patient
cll
high
preval
ebv
thu
possess
ebvspecif
memori
cell
high
frequenc
cell
incorpor
exosom
dual
function
confer
bcell
tropism
serv
immunodomin
viral
antigen
incorpor
viral
protein
tumorspecif
antigen
straightforward
cellular
immun
system
cancer
patient
usual
impair
virusspecif
immun
respons
detect
even
latestag
patient
lymphocyt
specif
herp
virus
often
present
high
number
given
fact
vast
major
cll
patient
seroposit
ebv
ebv
protein
potenti
promis
neoantigen
bcll
cell
exploit
redirect
strong
antivir
cellular
immun
respons
leukem
cell
base
result
propos
new
immunotherapeut
approach
bcll
base
simultan
target
transfer
function
ebv
protein
onto
malign
cell
use
exosom
major
envelop
protein
ebv
confer
viral
bcell
tropism
interact
complement
receptor
highli
express
b
lymphocyt
gener
modifi
exosom
produc
cell
result
incorpor
particl
profound
bcell
tropism
similar
wildtyp
ebv
vesicl
specif
effici
bind
b
cell
addit
serv
viral
neoantigen
bcll
cell
also
found
exosom
cell
function
activ
demonstr
induct
immun
accessori
molecul
b
target
cell
probabl
pathway
taken
togeth
experi
suggest
leukemia
cell
treat
exosom
effici
stimul
subsequ
kill
autolog
bcll
cytolyt
lymphocyt
summari
result
demonstr
modifi
exosom
carri
ebv
protein
display
distinct
tropism
normal
leukem
b
cell
effici
transfer
function
protein
onto
cell
leukem
b
cell
treat
particl
acquir
activ
phenotyp
becom
potent
stimul
autolog
lymphocyt
engin
exosom
easili
gener
readili
scale
clinic
applic
addit
individu
tailor
express
addit
accessori
molecul
like
fa
ligand
altern
viral
molecul
target
class
cell
like
macrophag
dc
gener
modifi
exosom
limit
cell
use
proofofconcept
instead
cell
line
approv
human
therapi
fibroblast
also
test
option
origin
exosom
facilit
transit
clinic
trial
modifi
exosom
thu
regard
power
promis
tool
variou
immunotherapeut
approach
peripher
blood
sampl
obtain
patient
diagnosi
bcll
inform
consent
approv
institut
ethic
committe
normal
blood
sampl
taken
healthi
volunt
mononuclear
cell
isol
densiti
gradient
centrifug
fh
b
cell
purifi
mac
bead
miltenyi
bergisch
gladbach
germani
cell
cultur
atmospher
standard
medium
fetal
calf
serum
human
embryon
kidney
cell
line
spontan
releas
exosom
cell
cultur
supernat
gener
modifi
exosom
cell
cotransfect
express
plasmid
andor
gfp
isol
exosom
ml
condit
supernat
collect
three
day
later
steril
filtrat
subject
repeat
centrifug
increas
centrifug
forc
min
x
g
min
x
g
heraeu
follow
h
x
g
beckman
ultracentrifug
swingout
rotor
pellet
particl
wash
resuspend
volum
pb
contain
proteas
inhibitor
complet
mini
roch
protein
content
analyz
lowri
microassay
use
reagent
purchas
biorad
munich
germani
exosom
purifi
flotat
iodixanol
gradient
sigma
aldrich
deisenhofen
germani
bcll
cell
cultiv
exosom
final
volum
ml
two
day
induct
surfac
accessori
molecul
measur
flow
cytometri
use
fac
calibur
flow
cytomet
becton
dickinson
beadcoupl
assay
surfactantfre
sulfatealdehyd
latex
bead
incub
exosom
min
room
temperatur
ml
pb
ad
bead
incub
anoth
hour
bead
wash
three
time
pb
fc
analyz
antibodi
specif
purchas
santa
cruz
biotechnolog
e
kremmer
munich
provid
antibodi
fluorochromelabel
secondari
antibodi
obtain
becton
dickinson
heidelberg
germani
immunotool
friesoyt
germani
vesicl
prepar
spot
onto
pvdf
membran
incub
specif
primari
antibodi
hrpcoupl
secondari
antibodi
develop
ecl
system
ge
healthcar
gangliosid
detect
colera
toxin
sigma
aldrich
order
reactiv
ebvspecif
tcell
bcll
blood
sampl
cell
cultiv
exosom
final
volum
ml
restimul
perform
day
ad
lethal
irradi
autolog
pbmc
load
exosom
fresh
medium
ad
week
day
cell
analyz
flow
cytometri
lineag
marker
assay
perform
accord
manufactur
instruct
mabtech
uppsala
sweden
tcell
clone
use
describ
elsewher
cell
test
triplic
calcein
releas
assay
perform
describ
previous
briefli
target
cell
label
calceinam
solut
medium
min
intens
wash
cell
either
incub
exosom
h
load
cllspecif
peptid
aasequ
vlfylgqyi
ylapengyl
elfqdlsql
h
left
untreat
cytotox
assay
perform
time
period
h
use
effectortargetratio
calcein
releas
supernat
quantifi
excit
emiss
wavelength
nm
nm
respect
plateread
perkin
elmer
waltham
experi
perform
least
three
time
